CONCERT PHARMACEUTICALS INC (CNCE) Stock Price, Quote, News and Overview
NASDAQ:CNCE - Nasdaq - US2060221056 - Common Stock - Currency: USD
CNCE Quote, Performance and Key Statistics
8.37
+0.01 (+0.12%)
The current stock price of CNCE is 8.37 USD. In the past month the price decreased by -0.36%. In the past year, price increased by 190.63%.
CNCE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CNCE
Company Profile
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. The company is headquartered in Lexington, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2014-02-13. The firm is focused on developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that discovered through deuterated chemical entity Platform (DCE platform). The firm is evaluating CTP-543 in a Phase III clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. Through DCE Platform, the Company has discovered and developed novel drugs designed to have properties, including enhanced clinical safety, tolerability or efficacy based on compounds. DCE technology has range of potential across numerous therapeutic areas, including for chronic diseases for which medicines are continually used by patients. The firm is assessing earlier-stage pipeline candidates as potential development candidates, including a once-daily, modified release formulation of CTP-543.
Company Info
CONCERT PHARMACEUTICALS INC
Suite 500, 99 Hayden Avenue
Lexington MASSACHUSETTS 02421 US
CEO: Roger D. Tung
Employees: 64
Company Website: https://www.concertpharma.com/
Phone: 17818600045.0
CONCERT PHARMACEUTICALS INC / CNCE FAQ
What is the stock price of CONCERT PHARMACEUTICALS INC today?
The current stock price of CNCE is 8.37 USD. The price increased by 0.12% in the last trading session.
What is the ticker symbol for CONCERT PHARMACEUTICALS INC stock?
The exchange symbol of CONCERT PHARMACEUTICALS INC is CNCE and it is listed on the Nasdaq exchange.
On which exchange is CNCE stock listed?
CNCE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CONCERT PHARMACEUTICALS INC stock?
11 analysts have analysed CNCE and the average price target is 11.9 USD. This implies a price increase of 42.17% is expected in the next year compared to the current price of 8.37. Check the CONCERT PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CONCERT PHARMACEUTICALS INC worth?
CONCERT PHARMACEUTICALS INC (CNCE) has a market capitalization of 401.95M USD. This makes CNCE a Small Cap stock.
How many employees does CONCERT PHARMACEUTICALS INC have?
CONCERT PHARMACEUTICALS INC (CNCE) currently has 64 employees.
What are the support and resistance levels for CONCERT PHARMACEUTICALS INC (CNCE) stock?
CONCERT PHARMACEUTICALS INC (CNCE) has a support level at 8.37 and a resistance level at 8.38. Check the full technical report for a detailed analysis of CNCE support and resistance levels.
Is CONCERT PHARMACEUTICALS INC (CNCE) expected to grow?
The Revenue of CONCERT PHARMACEUTICALS INC (CNCE) is expected to decline by -99.69% in the next year. Check the estimates tab for more information on the CNCE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CONCERT PHARMACEUTICALS INC (CNCE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CNCE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CNCE, evaluating the profitability, health, valuation and growth aspects
- CONCERT PHARMACEUTICALS INC (CNCE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CONCERT PHARMACEUTICALS INC (CNCE) Sales and EPS estimates to see what analysts future expectations are.
- CONCERT PHARMACEUTICALS INC (CNCE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CONCERT PHARMACEUTICALS INC (CNCE) Insider and Institutional Ownership to learn about the owners and their transactions.
- CONCERT PHARMACEUTICALS INC (CNCE) Stock Chart to make your own analysis
- CONCERT PHARMACEUTICALS INC (CNCE) Latest news and press-releases to stay up to date.
Does CONCERT PHARMACEUTICALS INC (CNCE) stock pay dividends?
CNCE does not pay a dividend.
When does CONCERT PHARMACEUTICALS INC (CNCE) report earnings?
CONCERT PHARMACEUTICALS INC (CNCE) will report earnings on 2023-05-03.
What is the Price/Earnings (PE) ratio of CONCERT PHARMACEUTICALS INC (CNCE)?
CONCERT PHARMACEUTICALS INC (CNCE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.21).
CNCE Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to CNCE. When comparing the yearly performance of all stocks, CNCE is one of the better performing stocks in the market, outperforming 99.23% of all stocks.
CNCE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CNCE. The financial health of CNCE is average, but there are quite some concerns on its profitability.
CNCE Financial Highlights
Over the last trailing twelve months CNCE reported a non-GAAP Earnings per Share(EPS) of -3.21. The EPS decreased by -62.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CNCE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to CNCE. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -22.75% and a revenue growth -99.69% for CNCE